Protara Therapeutics Inc. (TARA)
Protara Therapeutics Statistics
Share Statistics
Protara Therapeutics has 38.58M shares outstanding. The number of shares has increased by 78.57% in one year.
| Shares Outstanding | 38.58M |
| Shares Change (YoY) | 78.57% |
| Shares Change (QoQ) | 7.13% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,237 |
| FTD / Avg. Volume | 0.36% |
Short Selling Information
The latest short interest is 2.03M, so 5.52% of the outstanding shares have been sold short.
| Short Interest | 2.03M |
| Short % of Shares Out | 5.52% |
| Short % of Float | 6.41% |
| Short Ratio (days to cover) | 7.06 |
Valuation Ratios
The PE ratio is -2.44 and the forward PE ratio is -1.66. Protara Therapeutics's PEG ratio is 0.06.
| PE Ratio | -2.44 |
| Forward PE | -1.66 |
| PS Ratio | 0 |
| Forward PS | 0.6 |
| PB Ratio | 0.65 |
| P/FCF Ratio | -3.03 |
| PEG Ratio | 0.06 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Protara Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.71, with a Debt / Equity ratio of 0.03.
| Current Ratio | 15.71 |
| Quick Ratio | 15.71 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | -0.09 |
| Debt / FCF | -0.12 |
| Interest Coverage | -11.78 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,592,714.29 |
| Employee Count | 28 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 19.03% in the last 52 weeks. The beta is 1.59, so Protara Therapeutics's price volatility has been higher than the market average.
| Beta | 1.59 |
| 52-Week Price Change | 19.03% |
| 50-Day Moving Average | 4 |
| 200-Day Moving Average | 3.35 |
| Relative Strength Index (RSI) | 39.74 |
| Average Volume (20 Days) | 347,785 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -49.15M |
| Net Income | -44.6M |
| EBITDA | -49.15M |
| EBIT | -40.42M |
| Earnings Per Share (EPS) | -2.17 |
Balance Sheet
The company has 162.8M in cash and 4.48M in debt, giving a net cash position of 158.31M.
| Cash & Cash Equivalents | 162.8M |
| Total Debt | 4.48M |
| Net Cash | 158.31M |
| Retained Earnings | -244.98M |
| Total Assets | 181.45M |
| Working Capital | 161.19M |
Cash Flow
In the last 12 months, operating cash flow was -35.81M and capital expenditures -63K, giving a free cash flow of -35.87M.
| Operating Cash Flow | -35.81M |
| Capital Expenditures | -63K |
| Free Cash Flow | -35.87M |
| FCF Per Share | -1.74 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TARA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for TARA is $21.5, which is 525% higher than the current price. The consensus rating is "Buy".
| Price Target | $21.5 |
| Price Target Difference | 525% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Stock Splits
The last stock split was on Jan 10, 2020. It was a backward split with a ratio of 1:40.
| Last Split Date | Jan 10, 2020 |
| Split Type | backward |
| Split Ratio | 1:40 |
Scores
| Altman Z-Score | 3.67 |
| Piotroski F-Score | 2 |